Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today ...

That conversation stuck with me, especially in the context of the BYD Seal 5 DM-i I rode and drove for three days to Zambales ...

Sphere Bio's Cyto-Cellect Assay Kit integrates viability and antibody detection, streamlining workflows and ensuring optimal selection of high-producing clones.

This came as part of the continuous regulatory surveillance, where drug samples are picked from sales/distribution points, ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...